Coronavirus (COVID-19): visiting The Royal Marsden suspended

Coronavirus (COVID-19) latest: Visiting The Royal Marsden is still suspended, but we want to reassure our patients, their families and anyone worried about cancer during this difficult time that we are still delivering treatment - the hospital is open. Please see more information here about how we are keeping everyone safe.

Dr Vincent Khoo

Consultant in Clinical Oncology MBBS FRACR FRCR MD

Specialism: Radiotherapy, Urology

Available at: Chelsea

Special interests:

  • intensity modulated and image guided radiotherapy including CyberKnife
  • chemotherapy
  • hormone therapy
  • robotic brachytherapy
  • clinical trials


Dr Khoo has both a private and an NHS practice at The Royal Marsden. He is a Consultant in Clinical Oncology at The Royal Marsden and Honorary Consultant at St George’s Hospitals. He is Honorary Reader at The Institute of Cancer Research, University of London. He was previously Head of Department of Clinical Oncology at The Royal Marsden. He qualified in medicine in 1985 and has trained and worked in clinical oncology in the UK, USA and Australia.
He is Adjunct Professor, Department of Medical Imaging and Radiation Sciences, Monash University and Honorary Associate Professor, Department of Medicine, University of Melbourne and Austin Health. He leads collaborative research groups with these Australian centres.
Dr Khoo specialises in urological cancers with interests in combination systemic Clinical Trials. He is a member of several national and international committees including:
  • Chair of the NCRN Penile Cancer Clinical Studies 
  • NCRN Renal & Bladder Clinical Studies Group
  • European Society for Therapeutic Radiation and Oncology (ESTRO)
  • European Cancer Conference (ECCO)
  • European Society of Medical Oncology (ESMO)
  • International Targeted Prostate Cancer Screening Study (IMPACT)
He is specialist advisory and reviewer to CancerBackup, CancerHelp, National Horizon Scanning Centre, International Union against Cancer (UICC) and several international scientific journals/cancer funds. He has research interests in combined modality therapy, multi-modality imaging, technical and image-guided radiotherapy.
He is Clinical Lead, Clinical Trials Unit Urology Chelsea (CTUUC) at The Royal Marsden’s Chelsea branch and offers a comprehensive array of therapies, from stereotactic radiotherapy (CyberKnife) to image guided intensity modulated and adaptive radiotherapy, and prostate brachytherapy to systemic therapies such as hormonal, targeted therapies and chemotherapy as well as Phase I to IV Clinical Trials with these therapy agents.

Clinical units